Heron Therapeutics (Heron Therapeutics) Debt-to-Asset : 0.81 (As of Dec. 2023)

View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics Debt-to-Asset?

Heron Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.1 Mil. Heron Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $176.6 Mil. Heron Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $222.5 Mil. Heron Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.81.

Heron Therapeutics Debt-to-Asset Historical Data

The historical data trend for Heron Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics Debt-to-Asset Chart

Heron Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.07

0.52

0.63

0.81

Heron Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.63	0.71	0.78	0.79	0.81

Competitive Comparison of Heron Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Heron Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heron Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Debt-to-Asset falls into.

Heron Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Heron Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.075	+	176.553)	/	222.506
	=	0.81

Heron Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.075	+	176.553)	/	222.506
	=	0.81

Heron Therapeutics (NAS:HRTX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Heron Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Heron Therapeutics (Heron Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

AXD2:Germany AXD2:Germany

Address

4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.herontx.com

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

Executives

William P Forbes	officer: EVP, Chief Development Officer	C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte	officer: EVP, Chief Financial Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler	director	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp	other: See Footnote 2	1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen	other: See Footnote 1	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp	other: See Footnote 1	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman	other: See Footnote 2	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian	director	RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121